Occult hepatitis B and its role in spread of the infection and development of hepatocellular carcinoma (review)
https://doi.org/10.25016/2541-7487-2015-0-3-78-87
Abstract
Occult hepatitis B is a form of chronic viral hepatitis B infection in which its main serological marker (HBsAg) is absent, and HBV DNA is determined with a high level of replication in the liver and rarely in the serum. Occult hepatitis B can be detected only by one marker - total antibody to the core protein of virus – anti-HBc. The factors influencing the occurrence of occult hepatitis B, its distribution among the population and the development of hepatocellular carcinoma are reviewed in the paper. The need to develop new diagnostic test systems for blood and organ donors as well as high-risk persons is discussed.
Keywords
virial hepatitis B,
occult hepatitis B,
HBsAg,
anti-HBc,
HBc,
anti-HBs,
DNA HBV,
hepatocellular carcinoma
About the Authors
A. G. Rakhmanova
Health Committee of Saint Petersburg Government,
Saint Petersburg AIDS Center,
Pavlov First Saint Petersburg State Medical University
Russian Federation
Russian Federation
Dr. Med. Sci. Prof., chief infectious disease specialist of the Health Committee of Saint Petersburg Government, deputy head of the Saint Petersburg AIDS Center, Professor of socially significant infections department, Pavlov First Saint Petersburg State Medical University (Russia, 197022, Saint Petersburg, L’va Tolstogo Str., 6/8)
P. A. Aleksandrov
State outpatient department N 4
Russian Federation
Russian Federation
infection disease doctor, State outpatient department N 4 (Russia, 199178, Saint Petersburg, Bol’shoy prospekt, 59)
V. V. Sharoyko
Institute of Chemistry of Saint-Petersburg State University
Russian Federation
Russian Federation
Dr. Вiol. Sci., PhD, leading scientist of the interdepartment biomedicine chemistry
laboratory, Institute of Chemistry of Saint-Petersburg State University (Russia, 198504, Saint-Petersburg, Petrodvorets, Universitetskii pr., 26)
References
1. Morozov I.A., Il’chenko L.Yu., Gromova N.I. [et al.]. Problemy skrytoi infektsii, vyzvannoi virusom gepatita V [Problems of latent infection caused by the hepatitis B virus]. Rossiiskii zhurnal gastroenterologii, gepatologii i koloproktologii [The Russian Journal of Gastroenterology, Hepatology and Coloproctology]. 2012. N 4. Pp. 58–66. (In Russ.)
2. Rakhmanova A.G. Kliniko-morfologicheskie sopostavlenii okkul’tnogo gepatita V : po materialam klinicheskoi infektsionnoi bol’nitsy im. S.P. Botkina 2010–2013 gg. [Clinical and morphological comparison of occult hepatitis B: data of Clinical Infectious Disease Hospital named after S.P. Botkin, 2010-2013]. Infektsionnye bolezni–2014 [Infectious Dseases-2014]. Sankt-Peterburg. 2014. Pp.198–203. (In Russ.)
3. Rekomendatsii po diagnostike i lecheniyu vzroslykh bol’nykh gepatitom V : utverzhdeny Ministerstvom zdravookhraneniya Rossii 06.08.2014 g. № 17-00-5704 [Recommendations for the diagnosis and treatment of adult patients with hepatitis B: approved by Russian Ministry of Health, 08.06.2014 N 17-00-5704]. Compilers: Ivashkin V.T., Yushchuk N.D., Maevskaya M. [et al.]. Moskva. 2014. 70 p. (In Russ.)
4. Profilaktika virusnogo gepatita V : sanitarno-epidemiologicheskie pravila SP 3.11.1.2341-08 [Prevention of hepatitis B: sanitation and epidemiological rules SP 3.11.1.2341-08]. Rossiiskaya gazeta [Russian Gazette]. 05.04.2008, N 4631. (In Russ.)
5. Semenov A.V., Vashukova S.S, Rakhmanova A.G. Predvaritel’nye itogi laboratornoi diagnostiki virusnykh gepatitov V i S v g. Sankt-Peterburge [Preliminary results of laboratory diagnostics of viral hepatitis B and C in St. Petersburg] Medikobiologicheskie i sotsial’no-psikhologicheskie problemy bezopasnosti v chrezvychaynykh situatsiyakh [Medical-Biological and Socio-Psychological Problems of Safety in Emergency Situations]. 2010. N 3. Pp. 61–64. (In Russ.)
6. Yushchuk N.D., Klimanova E.A., Znoiko O.O. Protokol diagnostiki i lecheniya bol’nykh virusnymi gepatitami V i S [Guidelines for diagnostics and treatment of patients with viral hepatitis B and C]. Rossiiskii zhurnal gastroenterologii, gepatologii I koloproktologii [The Russian Journal of Gastroenterology, Hepatology and Coloproctology]. 2010. N 6. Pp. 4–60. (In Russ.)
7. Allain J.P., Mihaljevich I., Gonzalez-Fraile M.I. [et al.]. Infectivity of blood products from donors with occult hepatitis B virus infection. Transfusion. 2013. Vol. 53, N 7. Pp. 1405–1415.
8. Arababadi M.K., Hassanshahi G., Pourfathollah A.A. [et al.]. Post-Transfusion Occult Hepatitis B (OBI): A Global Challenge for Blood Recipients and Health Authorities. Hepatitis Monthy. 2011. Vol. 11, N 9. Pp. 714–718.
9. Beck J., Nassal M. Hepatitis B virus replication. World J. Gastroenterol. 2007. Vol. 13, N 1. Pp. 48–64.
10. Berger A., Preiser W., Kachel H.G. [et al.]. HBV reactivation after kidney transplantation. J. Clin. Virol. 2005. Vol. 32, N 2. Pp. 162–165.
11. Castillo J., Martinez-Araj O.T., Bartolamej M.R. [et al.]. High prevalence of occult. Hepatitis C virus infection in patients with primary and secondary glomerular nephropathies. Ridney international. 2014. Vol. 86, N 3. Pp. 619–624.
12. Chen C.J., Yang H.I., Su J. [et al.]. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006. Vol. 295, N 1. Pp. 65–73.
13. Chevallier-Queyron P., Chemin I. Immunostochimistry as a Tool for Chronic Hepatitis Diagnosis, Liver Biopsy. The important practical results and modern lines in studying diseases of the stomach and duodenum. Ed. Hirokazu Takahashi. University Campus STeP Ri. 2011. P. 56.
14. Ciesek S., Helfritz F.A., Lehmann U. [et al.]. Persistence of occult hepatitis B after removal of the hepatitis B virus-infected liver. J. Infect. Dis. 2008. Vol. 197, N 3. Pp. 355–360.
15. Du W., Zheng Z., Han S. [et al.]. HBV reactivation in an occult HBV infection patient treated with prednisone for nephrotic syndrome: case report and literature review. BMC Infect. Dis. 2013. Vol. 13. Pp. 394–398.
16. EASL Clinical Practice Guidelines. Management of chronic hepatitis B virus infection. J. Hepatol. 2012. Vol. 57. N 1. Pp. 167–185.
17. El-Serag H.B., Rudolph K.L. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007. Vol. 132, N 7. Pp. 2557–2576.
18. Fang Y., Shang Q.L., Liu J.Y. [et al.]. Prevalence of occult hepatitis В virus infection among hepatopathy patients and healthy people in China. J. Infect. 2009. Vol. 58. N 5. Pp. 383–388.
19. Filippini Р., Coppola N., Pisapia R. [et al.]. Impact of occult hepatitis В virus infection in HIV patients naive for antiretroviral therapy. Aids. 2006. Vol. 20, N 9. Pp. 1253–1260.
20. Fontenele A.M.M., Filho N.S., Ferreira A.S.P. Occult hepatitis B in patients on hemodialysis: a review. Annals of Hepatology. 2013. Vol.12, N 4. Pp. 359–363.
21. Gonzalez J., Nararro J., Rodrigersde S.E., Martinez A. Diagnosis and management of occult, hepatitis B virus infection: a short revive. Hepatology. 2015. Vol. 3, N 1. Pp. 63–69.
22. Hass M. Functional analysis of hepatitis B virus reactivating in hepatitis B surface antigen-negative individuals. Hepatology. 2005. Vol. 42, N 1. Pp. 93–103.
23. Hofer M., Joller-Jemelka H.I. Grob P.J. [et al.]. Frequent chronic hepatitis B virus infection in HIV-infected patients positive for antibody to hepatitis В core antigen only. Swiss HIV Cohort Study. Eur. J. Clin. Microbiol. Infect. Dis. 1998. Vol. 17, N 1. Pp. 6–13.
24. Huang X., Hollinger F. Occult hepatitis B virus infection and hepatocellular carcinoma a systematic review. J. Viral Hepatology. 2014. Vol. 21, N 3. Pp. 153–162.
25. Hui C.K. Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology. 2006. Vol. 131. N 1. Pp. 59–68.
26. Kay A., Zoulim F. Hepatitis B virus genetic variability and evolution. Virus research. 2007. Vol. 127, N 2. Pp. 164–176.
27. Ke Q.H. Occult hepatitis B virus infection and its clinical implications. J. of Viral Hepatitis. 2002. Vol. 9, N 4. Pp. 243–257.
28. Lai C.L., Yuen M.F. Prevention of hepatitis B virus-related hepatocellular carcinoma with antiviral therapy // Hepatology. 2013. Vol. 57, N 1. Pp. 399–408.
29. Larrubia J.R. Occult hepatitis В virus infection: A complex entity with relevant cliniсal implications. World J. Gastroenterol. 2011. Vol. 17, N 12. Pp. 1529–1530.
30. Lee W.M. Hepatitis B virus infection. N. Engl. J. Med. 1997. Vol. 337, N 24. Pp. 1733–1745.
31. Levrero M., Pollicino T., Petersen J. [et. al.]. Control of cccDNA function in hepatitis B virus infection. J. Hepatol. 2009. Vol. 51, N 3. Pp. 581–592.
32. Locarnini S. Molecular Virology of Hepatitis B Virus. Seminars in Liver Disease. 2004. Vol. 24, Suppl. 1. Pp. 3–10.
33. Lok A.S. [et al.]. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology. 1991. Vol. 100, N 1. Pp. 182–188.
34. Manzano-Alonso M.L., Castellano-Tortajada G. [et al.]. Reactivation of hepatitis B virus infection after cytotoxic chemotherapy or immunosuppressive therapy. World J. Gastroenterol. 2011. Vol. 17, N. 12. Pp. 1531–1537.
35. Martinez MC, Kok CC, Baleriola C, [et al.]. Investigation of occult hepatitis B virus infection in anti-hbc positive patients from a liver clinic. PLoS One. 2015. Vol. 12, N 10. Pp. 1–13.
36. Minuk G.Y., Sun D.F., Greenberg R. [et al.]. Occult hepatitis В virus infection in a North American adult hemodialysis patient population. J. Hepatol. 2004. Vol. 40, N 5. Pp. 1072–1077.
37. Morales R.J., Vargas G. Occult HBV infection: A faceless enemy in liver cancer development viruses. Viruses. 2014. Vol. 6, N 4. Pp. 1590–1611.
38. Nassal M. Hepatitis B viruses: reverse transcription a different way. Virus Res. 2008. Vol. 134, N 1. Pp. 235–249.
39. Parés A., Barrera J.M., Caballería J. [et al.]. Hepatitis C virus antibodies in chronic alcoholic patients: association with severity of liver injury. J. Hepatology. 1990. Vol. 12, N 6. Pp. 1295–1299.
40. Parkin D.M. The global health burden of infection-associated cancers in the year 2002. Int. J. Cancer. 2006. Vol.118, N 12. Pp. 3030–3044.
41. Pettigrew N.M., Goudie R.B., Russell R.I., Chaudhuri A.K. Evidence for a role of hepatitis virus B in chronic alcoholic liver disease. Lancet. 1972. Vol 7, N 2. Pp. 724-725.
42. Pollicino T., Saitta C., Raimondo G. Hepatocellular carcinoma: the point of view of the hepatitis B virus. Carcinogenesis. 2011. Vol. 32, N 8. Pp. 1122–1132.
43. Pollicino T., Sailta C. Occult hepatitis B virus and hepatocellular carcinoma. World J. Gastroenterology. 2014. Vol. 28, N 20. Pp. 5951–5961.
44. Pollicino T., Raimondo G. Occult hepatitis B infection. J. Hepatol. 2014. Vol. 61, N 3. Pp. 688–689.
45. Raimondo G. Burk R.D., Lieberman H.M. [et al.]. Interrupted replication of hepatitis B virus in liver tissue of HBsAg carriers with hepatocellular carcinoma. Virology. 1988. Vol. 166, N 1. Pp. 103–112.
46. Raimondo G., Allain J.P., Brunetto M.R. [et al.]. Statements from the Taormina expert meeting on occult hepatitis B virus infection. J. Hepatol. 2008. Vol. 49, N 4. Pp. 652–657.
47. Raimondo G., Pollicino Т., Romano L., Zanetti A.R. A 2010 update on occult hepatitis Binfection. Pathol. Biol. 2010. Vol. 58, N 4. Pp. 254–257.
48. Raimondo G., Caccamo G., Filomia R., Pollicino T. Occult HBV infection. Semin Immunopathol. 2013. Vol. 35, N 1. Pp.n 39–52.
49. Samal J., Kandpal M., Vivekanandan P. Molecular mechanisms underlying occult hepatitis B virus infection. Clin. Microbiol. Rev. 2012. Vol. 25, N 1. Pp. 142–163.
50. Shi Y., Wu Y.H., Wu W. [et. al]. Association between occult hepatitis B infection and the risk of hepatocellular carcinoma: a meta-analysis. Liver Int. 2012. Vol. 32, N 1. Pp. 231–240.
51. Squadrito G., Spinella R., Raimondo G. The Clinical Significance of occult HBV infection. Annals of Gastroenterology. 2014. Vol. 27, N 1. Pp. 15–19.
52. Torbenson M., Thomas D.L. Occult hepatitis B. Lancet Infect Dis. 2002. Vol. 2, N 8. Pp. 479–486.
53. Urashima T., Saigo K., Kobayashi S. [et al.]. Identification of hepatitis B virus integration in hepatitis C virus-infected hepatocellular carcinoma tissues. J. Hepat. 1997. Vol. 26. N 4. Pp. 771-778.
54. Urban S., Schulze A., Dandri M., Petersen J. The replication cycle of hepatitis B virus. J. Hepatol. 2010. Vol. 52, N 2. Pp. 282–284.
55. Yan H., Zhong G., Xu G. [et al.]. Sodium taurocholatecotransporting polypeptide is a functional receptor for human hepatitis B and D virus. Elife. 2012. Vol. 13, N 1. Pp. 1–28.
56. Yang H.I., Yuen M.F., Chan H.L. [et al.]. Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score. Lancet Oncol. 2011. Vol. 12. N 6. Pp. 568–574.
57. Yeo W. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J. Clin. Oncol. 2009. Vol. 27, N 4. Pp. 605–611.
58. Zanetti AR, Van Damme P, Shouval D. The global impact of vaccination against hepatitis B: a historical overview. Vaccine. 2008. Vol. 26, N 18. Pp. 6266–6273.
59. Zoulim F. New insight on hepatitis B virus persistence from the study of intrahepatic viral cccDNA. J. Hepatol. 2005. Vol. 42. N 3. Pp. 302–308.
Review
For citations:
Rakhmanova A.G., Aleksandrov P.A., Sharoyko V.V. Occult hepatitis B and its role in spread of the infection and development of hepatocellular carcinoma (review). Medicо-Biological and Socio-Psychological Problems of Safety in Emergency Situations. 2015;(3):78-87. (In Russ.) https://doi.org/10.25016/2541-7487-2015-0-3-78-87
Views:
4625
Email this article 